BioPharmSignal logoBioPharmSignal

Biotech News

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

SCYNEXIS (SCYX)SCYNEXISCompany update

SCYX (SCYX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is scyx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

SCYXSCYNEXIS2026-03-31 10:40 EST

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYXSCYNEXIS2026-02-26 13:23 EST

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

ASMBAssembly Biosciences2025-11-07 13:00 EST

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

MBRXMoleculin Biotech, Inc.2026-05-21 21:02 EST

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

IMNNImunon2025-11-10 18:30 EST

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

IMNNImunon2026-03-31 12:00 EST

IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study

ENTAEnanta Pharmaceuticals2026-03-30 11:00 EST

Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists (AAI)

ENTAEnanta Pharmaceuticals2026-02-10 12:00 EST

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

AVIRAtea2026-05-13 11:00 EST

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline

View all latest news

SCYNEXIS

Metabolic Kidney-Disease Lead Program SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770. The program is being advanced for autosomal dominant polycystic kidney disease, where AMPK activation may address multiple drivers of disease progression. Antifungal Franchise SCY-247 is...

Recent company news

SCYXSCYNEXIS2026-06-30 12:00 EST

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYXSCYNEXIS2026-05-22 20:15 EST

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYXSCYNEXIS2026-05-11 20:23 EST

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYXSCYNEXIS2026-05-07 01:15 EST

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYXSCYNEXIS2026-03-31 10:45 EST

SCYNEXIS Announces $40.0 Million Private Placement

Stock data

Close
5.20 USD
Market cap
50.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States